1. Clinical Pathology Evaluation in Pet Rabbits Vaccinated Against Rabbit Hemorrhagic Disease Virus 2 (RHDV2).
- Author
-
Griffin, Chris, Locke, Salina, Montiani-Ferreira, Fabiano, Lopes Grego, Andressa, Soto, Jeny, and Cray, Carolyn
- Subjects
- *
BOOSTER vaccines , *RABBITS , *HEALTH of pets , *LABORATORY rabbits ,RABBIT diseases - Abstract
Simple Summary: Rabbit hemorrhagic disease virus 2 (RHDV2) was reported in the United States in 2018 and has since spread across most of the country where it has a potential for adverse impacts on ecosystems, economic losses, and pet rabbit health. Using an emergency use authorized vaccine, seroconversion and protection was demonstrated in 3- to 7-week-old specific pathogen free laboratory rabbits. The purpose of the current study was to examine this protocol in pet rabbits, which would be inclusive of varied breeds and ages. Importantly, no significant differences were observed in routine clinical pathology measures. Seroconversion was also observed but was variable, and lower levels of seroconversion were associated with increased age. In general, while variable outcomes to vaccination are expected, these preliminary data underlie the importance of examining the response of pet rabbits to help optimize new vaccine protocols. We propose this will complement traditional vaccine studies, aid in maintaining the health of pet rabbits, and help in the ultimate control of this highly infectious virus. A recombinant vaccine for rabbit hemorrhagic disease virus 2, a highly pathogenic virus, was granted emergency use authorization in the United States after the detection and spread of the virus starting in 2018. The goal of the current study was to assess pet rabbits (n = 29) through physical examination and routine clinical pathology testing using repeated assessments post-vaccination. In addition, seroconversion was also monitored after the initial vaccination and booster vaccination. Neither owners nor clinicians detected any physical abnormalities in relationship to the vaccine protocol. Hematological and clinical biochemistry testing showed some changes although median values were within species specific reference intervals. A significant increase in antibody levels was observed at day 21 (post-initial vaccination) and day 49 (post-booster vaccination) versus that present at baseline (p < 0.0001). However, variability in study rabbits was noted with some individuals showing low antibody levels as well as a lower overall response in older rabbits (r = −0.56, p = 0.006). A second cohort of rabbits was assessed at 11–12 months post-initial vaccination. In this second group, antibody levels were not significantly different from baseline levels (p = 0.21). Additional studies should be conducted to further define the variability in seroconversion and the term of protection in pet rabbits as the industry moves forward in the optimization of RHDV2 vaccines. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF